In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz Pharmaceuticals Improvises Its Way To A Turnaround

Executive Summary

A day after specialty drug developer Jazz Pharmaceuticals Inc. announced plans to merge with Irish drugmaker Azur Pharma Ltd. in mid-September, the company had something new to celebrate. Jazz’s stock price reached an all-time high of $47.88 per share, giving the company a market valuation of almost exactly $2 billion.
Advertisement

Related Content

Jazz Tunes Up For Business Development
Jazz Cools On Women’s Health, Sells Unit To Meda
Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug
Jazz Pharmaceuticals' IPO: Taking Stock of VC Dilution
Jazz Pharmaceuticals: The Concept Bet, at a Whole New Level
Jazz Pharmaceuticals: The Concept Bet, at a Whole New Level

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel